CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-31 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +10,000 | $23.26 | $233K | 68,555 |
| 2026-08-31 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −10,000 | $70.24 | $702K | 58,555 |
| 2026-08-31 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −10,000 | 0 | ||
| 2026-07-30 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +14,000 | $23.26 | $326K | 72,555 |
| 2026-07-30 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −14,000 | $79.88 | $1.1M | 58,555 |
| 2026-07-30 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −14,000 | 10,000 | ||
| 2026-07-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,000 | $23.26 | $349K | 73,555 |
| 2026-07-01 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,000 | $85.80 | $1.3M | 58,555 |
| 2026-07-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,000 | 24,000 | ||
| 2026-06-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,000 | $23.26 | $349K | 73,555 |
| 2026-06-01 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,000 | $74.08 | $1.1M | 58,555 |
| 2026-06-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,000 | 39,000 | ||
| 2026-05-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +11,333 | $39.13 | $443K | 69,888 |
| 2026-05-05 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −11,333 | $77.25 | $875K | 58,555 |
| 2026-05-05 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −11,333 | 13,070 | ||
| 2026-05-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,857 | $37.63 | $597K | 74,412 |
| 2026-05-01 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,857 | $65.00 | $1.0M | 58,555 |
| 2026-05-01 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −15,857 | 0 | ||
| 2026-04-30 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +15,000 | $23.26 | $349K | 73,555 |
| 2026-04-30 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −15,000 | $63.26 | $949K | 58,555 |
Page 1 of 5 · 90 trades